Drugs / Kabiven®
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT03481894 | Mar 2018 → Mar 2020 | nutritional deficiency disease | Fresenius Kabi | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Kabiven | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03481894 ↗ |
| Known as | Kabiven for intravenous use (investigational drug) | “Kabiven® for intravenous use (investigational drug)” NCT03481894 ↗ |
| Modality | Other / unclassified | “Kabiven is a sterile, hypertonic emulsion in a three chamber container.” NCT03481894 ↗ |
| Route | Intravenous | “Route of Administration: Infusion into a central vein.” NCT03481894 ↗ |